Recent Quotes (30 days)

You have no recent quotes
chg | %

Guided Therapeutics Inc  

(Public, OTCBB:GTHP)   Watch this stock  
Find more results for OTC:GTHP
0.790
-0.130 (-14.12%)
Delayed:   1:59PM EDT
OTCBB data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.75 - 0.92
52 week 0.46 - 0.98
Open 0.92
Vol / Avg. 503,331.00/87,151.00
Mkt cap 49.13M
P/E     -
Div/yield     -
EPS -0.11
Shares 62.19M
Beta -1.20
Inst. own 0%
Aug 12, 2013
Q2 2013 Guided Therapeutics Inc. Earnings Release Add to calendar
May 15, 2013
Q1 2013 Guided Therapeutics Inc. Earnings Conference Call
May 13, 2013
Q1 2013 Guided Therapeutics Inc. Earnings Release
Mar 27, 2013
Q4 2012 Guided Therapeutics Inc. Earnings Conference Call
Mar 25, 2013
Q4 2012 Guided Therapeutics Inc. Earnings Release
  

Key stats and ratios

Q3 (Sep '12) 2011
Net profit margin -133.97% -183.43%
Operating margin -131.79% -186.53%
EBITD margin - -85.59%
Return on average assets -95.42% -161.48%
Return on average equity -336.01% -534.51%
Employees 35 -
Carbon Disclosure Rating - -

Address

Suite D, 5835 Peachtree Corners East
NORCROSS, GA 30092
United States - Map
+1-770-2428723 (Phone)
+1-770-2428639 (Fax)

Website links

External links

Discussion Group - Google Finance

Description

Guided Therapeutics, Inc., formerly SpectRx, Inc., is a medical technology company focused on developing medical devices. Its primary focus is the development of its cervical cancer detection technology (LightTouch) and extension of its cancer detection platform into other cancers, especially lung and esophageal. Its technology, including products in research and development, includes biophotonics technology for the non-invasive detection of cancers, including cervical cancer. LuViva is a non-invasive cervical cancer detection product of the Company. It is working with Konica Minolta Opto, Inc., a subsidiary of Konica Minolta, Inc., a Japanese corporation based in Tokyo (Konica Minolta) to adapt its cervical cancer detection technology for detection of lung cancer and esophageal cancer. As of December 31, 2012, the Company was engaged primarily in the research, development and testing of its LuViva non-invasive cervical cancer detection product and its core biophotonic technologies.

Officers and directors

Ronald W. Allen Independent Chairman of the Board
Age: 71
Mark L. Faupel Ph.D. President, Chief Executive Officer, Acting Chief Financial Officer, Director
Age: 57
Ronald W Hart PhD Independent Vice Chairman of the Board
Age: 70
Richard L. Fowler Senior Vice President - Engineering
Age: 56
John E Imhoff MD Independent Director
Age: 63
Michael C. James Independent Director
Age: 54
Jonathan M Niloff M.D. Independent Director
Age: 58
Linda M. Rosenstock M.D. Independent Director
Age: 62